CAH · 10-Q · 2026Q3 · Full report

Pharmaceutical Pricing Policy

CARDINAL HEALTH INC · 2026-11-05 · Importance 40 · Surprise 42

The Inflation Reduction Act has capped prices for certain drugs and is expected to continue adversely affecting Cardinal Health’s revenue, although profitability has not been materially impacted. The Executive Order titled “Delivering Most-Favored Nation Prescription Drug Pricing to American Patients” and other U.S. administrative policies may also affect branded pharmaceutical sales or profitability. The extent of future impacts is uncertain and depends on implementation timing and the size of any price reductions.

Key facts

• The Most-Favored Nation prescription drug pricing executive order and other administrative policies or actions may affect Cardinal Health branded pharmaceutical sales or profitability; the extent of future impacts is uncertain and may depend on implementation timing and price reductions. source
• The Inflation Reduction Act has and will continue to adversely impact Cardinal Health revenue by capping prices for certain drugs, but profitability has not been materially impacted. source
• Risks involving generic customer volumes, pricing changes, contract renewals, manufacturer pricing, and contract manufacturing and sourcing costs may affect Pharma segment profit and consolidated operating earnings during the remainder of fiscal 2027 and beyond. source